Anebulo Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021
Cash & Equivalents	11.25	14.55	19.99
Cash & Cash Equivalents	11.25	14.55	19.99
Cash Growth	-22.69%	-27.21%	-
Other Current Assets	0.42	1.03	1.67
Total Current Assets	11.67	15.58	21.65
Total Assets	11.67	15.58	21.65
Accounts Payable	0.53	0.38	0.11
Other Current Liabilities	0.53	0.13	0.13
Total Current Liabilities	1.07	0.51	0.24
Total Liabilities	1.07	0.51	0.24
Retained Earnings	-57.2	-45.47	-38.64
Shareholders' Equity	10.6	15.07	21.41
Net Cash / Debt	11.25	14.55	19.99
Net Cash / Debt Growth	-22.69%	-27.21%	-
Net Cash Per Share	0.45	0.62	1.47
Working Capital	10.6	15.07	21.41
Book Value Per Share	0.42	0.65	1.57

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).